848 Research news
Herceptin Biosimilar for Breast Cancer Now Available in US Market

Kanjinti (trastuzumab-anns), a biosimilar for Herceptin used to treat people diagnosed with HER2-positive breast cancer, is now available in the United States.

Jul 24, 2019 | Diagnosis and Targeted Therapy
Studies Show Risks and Benefits of Intraoperative Radiation Therapy

While two large studies suggest that intraoperative radiation therapy offers about the same overall survival and rates as whole-breast external beam radiation therapy for certain women diagnosed with early stage-breast cancer, there are concerns about local recurrence rates.

Modern Radiation Therapy Less Risky for Heart

A research letter estimates that modern radiation therapy techniques are less likely to cause heart problems than radiation therapy techniques used 20 or more years ago.

ASCO Publishes Special Series of Articles on Pain in People With Cancer

To provide practical approaches to managing cancer pain, the American Society of Clinical Oncology (ASCO) developed a special series of 14 articles on pain in people with cancer, including breast cancer.

Switching to New Doctor Delays Breast Cancer Treatment

People newly diagnosed with non-metastatic breast cancer who switched their care to a different doctor had various treatments delayed by more than a week.

Apr 15, 2019 | Diagnosis and Surgery
Genetic Testing Rates Are Low in Women Diagnosed With Breast Cancer, Ovarian Cancer

Only about 25% of women diagnosed with breast cancer and about 31% of women diagnosed with ovarian cancer have genetic testing.

Apr 18, 2019 | Diagnosis and Screening and Testing
Having a Partner Seems to Improve Quality of Life in Women With Sexual Side Effects From Breast Cancer Hormonal Therapy

A small study suggests that postmenopausal women with partners may have better quality of life than women without partners when experiencing a number of sexual side effects from hormonal therapy.

Kisqali Plus Faslodex Improves Overall Survival in Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Latest MONALEESA-3 results show Kisqali and Faslodex offer better overall survival than Faslodex alone in postmenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer that either hadn't been treated yet or had been treated with only one hormonal therapy.

Adding Keytruda to Chemotherapy Before Surgery for Early-Stage, Triple-Negative Breast Cancer Improves Response to Treatment

The combination of the immunotherapy Keytruda and chemotherapy before surgery to remove early-stage, triple-negative breast cancer led to a better pathologic complete response than chemotherapy alone.

Research Pinpoints Which Women Benefit From Bisphosphonates After Early-Stage Disease

A large study has found that bisphosphonates reduce the risk of distant breast cancer recurrence in postmenopausal women.

Jan 28, 2014 | Diagnosis, Risk Factors and Bone Health
Exercise Reduces Joint Pain Caused by Aromatase Inhibitors

A new study has found that exercise eases joint pain that's a common side effect of aromatase inhibitors.

CDK4/6 Inhibitor Plus Aromatase Inhibitor Helps Treat Breast Cancer, No Matter a Woman's Age

An analysis of three studies on different CDK4/6 inhibitors in combination with an aromatase inhibitor to treat postmenopausal women diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer found the treatment combination was effective in both younger and older women.

Experimental Tucatinib Improves Survival in Metastatic HER2-Positive Breast Cancer, May Be New Standard of Care

Adding experimental tucatinib to the standard of care of Herceptin and Xeloda improved both progression-free survival and overall survival in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.

Vitamin D Doesn't Seem to Be Linked to Recurrence Risk or Survival Rates, but There Are Questions About Study

A large study suggests that there is no link between vitamin D and overall survival or disease-free survival in women diagnosed with breast cancer with a high risk of recurrence. Still, there are questions about the study.

Jun 11, 2014 | Diagnosis, Nutrition and Risk Factors
Memory Problems After Chemotherapy Linked to Changes in Brain Activity

A small study suggests that changes in brain activity may be the cause of chemo brain.

Jun 24, 2014 | Diagnosis, Chemotherapy and Side Effects
Immunotherapy for Early-Stage Triple-Negative Breast Cancer: Understanding What Appear to Be Conflicting Results

Results from two studies on using the immunotherapy medicines Tecentriq or Keytruda along with chemotherapy to treat early-stage triple-negative breast cancer before surgery suggested that Keytruda offered benefits while Tecentriq did not.

Zoladex Helps Preserve Fertility in Women With Early-Stage, Hormone-Receptor-Negative Breast Cancer Treated With Chemotherapy

Five-year results found women diagnosed with early-stage, hormone-receptor-negative breast cancer who were treated with Zoladex in addition to chemotherapy before surgery were much less likely to be infertile after chemotherapy ended.

Women With Metastatic Breast Cancer Report "Catastrophic" Financial Effects

A national survey of more than 1,000 women diagnosed with metastatic breast cancer found that 35% had no insurance and nearly 70% said they were worried about financial problems because of cancer.

Oct 31, 2018 | Diagnosis and Day-to-Day Matters
Herceptin Biosimilar Seems as Effective as Herceptin

A study suggests that a drug that is a biosimilar to Herceptin, called MYL-1401O, is as effective as Herceptin and has similar side effects.

Jan 3, 2017 | Diagnosis and Targeted Therapy
Women Without Prescription Drug Coverage Less Likely to Start Hormonal Therapy

A study has found that women diagnosed with early-stage, hormone-receptor-positive breast cancer with no prescription drug coverage were less likely to start hormonal therapy than women who had insurance coverage for prescription drugs.

Herceptin Plus Tykerb After Surgery No Better Than Herceptin Alone for Early-Stage, HER2-Positive Disease

Women diagnosed with early-stage, HER2-positive breast cancer treated with both Herceptin and Tykerb after surgery had the same disease-free survival as women treated with only Herceptin after surgery.

Nov 28, 2015 | Diagnosis and Targeted Therapy
Triple-Negative Disease May Have New Treatment Option

Two studies presented at the 2015 San Antonio Breast Cancer Symposium suggest that adding carboplatin to the standard neoadjuvant chemotherapy regimen may improve outcomes for women diagnosed with triple-negative disease.

Dec 10, 2015 | Diagnosis and Chemotherapy
Prolia Reduces Recurrence Risk of Hormone-Receptor-Positive Disease in Women Taking Aromatase Inhibitors

A study has found that Prolia improved disease-free survival for postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer taking an aromatase inhibitor.

Lumpectomy Plus Radiation May Offer Survival Benefits for Early-Stage Disease

Another study suggests that lumpectomy plus radiation may offer survival benefits for some women diagnosed with early-stage disease.

Showing 24 of 848